Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 14;41(19):1810-1817.
doi: 10.1093/eurheartj/ehaa373.

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Iziah E Sama  1 , Alice Ravera  1   2 , Bernadet T Santema  1 , Harry van Goor  3 , Jozine M Ter Maaten  1 , John G F Cleland  4 , Michiel Rienstra  1 , Alex W Friedrich  5 , Nilesh J Samani  6 , Leong L Ng  6 , Kenneth Dickstein  7   8 , Chim C Lang  9 , Gerasimos Filippatos  10   11 , Stefan D Anker  12   13 , Piotr Ponikowski  14 , Marco Metra  2 , Dirk J van Veldhuisen  1 , Adriaan A Voors  1
Affiliations

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Iziah E Sama et al. Eur Heart J. .

Abstract

Aims: The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association with use of renin-angiotensin-aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-CoV-2 in patients on RAAS inhibitors.

Methods and results: We measured ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort). Results were validated in 1123 men and 575 women (validation cohort).The median age was 69 years for men and 75 years for women. The strongest predictor of elevated concentrations of ACE2 in both cohorts was male sex (estimate = 0.26, P < 0.001; and 0.19, P < 0.001, respectively). In the index cohort, use of ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists (MRAs) was not an independent predictor of plasma ACE2. In the validation cohort, ACE inhibitor (estimate = -0.17, P = 0.002) and ARB use (estimate = -0.15, P = 0.03) were independent predictors of lower plasma ACE2, while use of an MRA (estimate = 0.11, P = 0.04) was an independent predictor of higher plasma ACE2 concentrations.

Conclusion: In two independent cohorts of patients with heart failure, plasma concentrations of ACE2 were higher in men than in women, but use of neither an ACE inhibitor nor an ARB was associated with higher plasma ACE2 concentrations. These data might explain the higher incidence and fatality rate of COVID-19 in men, but do not support previous reports suggesting that ACE inhibitors or ARBs increase the vulnerability for COVID-19 through increased plasma ACE2 concentrations.

Keywords: ACE2; Coronavirus disease (COVID-19); Heart failure; Men.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the RAAS pathway.
Figure 2
Figure 2
ACE2 concentrations in patients with and without use of an ACE inhibitor, ARB, and MRA (index and validation). ACEi, use of an angiotensin-converting enzyme (ACE) inhibitor; ARB, use of an angiotensin receptor blocker; MRA, use of a mineralocorticoid receptor antagonist.
Take home figure
Take home figure
ADAM17 (A) and ACE2 (B) gene and protein Expression in human tissues. (Source A : https://www.proteinatlas.org/ENSG00000151694-ADAM17/tissue and B : https://www.proteinatlas.org/ENSG00000130234-ACE2/tissue).
None
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;doi: 10.1016/S2213-2600(20)30079-5. - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY,, Xiang J,, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J,, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;doi: 10.1056/NEJMoa2002032. - PMC - PubMed
    1. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol 2004;159:229–231. - PMC - PubMed
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;doi: 10.1001/jama.2020.4683. - PubMed
    1. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020;doi: 10.1093/jtm/taaa041. - PMC - PubMed

Publication types

MeSH terms

Substances